Bladder cancer often becomes resistant to standard treatments due to its ability to evade apoptosis, the primary form of cell death targeted by conventional therapies. In a recent study, researchers from China developed a nanomedicine that triggers ferroptosis—a different cell death pathway—without needing external activation. Their proposed system not only killed resistant cancer cells but also enhanced the immune system's anti-tumor response, offering a promising dual-action therapy for bladder cancers.

POSTECH and Linyi University develop ‘SLY,’ a Probe That Glows Yellow Only in Tumor Cells.

People who have survived cancer as children are at higher risk of developing severe COVID-19, even decades after their diagnosis. This is shown by a new study from Karolinska Institutet published in the journal The Lancet Regional Health – Europe.

A recent study published in Genes & Diseases reveals a novel role of XPR1 in promoting ovarian cancer growth by regulating autophagy and MHC-I expression. The research, conducted by scientists from Chongqing Medical University, identifies XPR1 as a critical factor influencing the aggressiveness of ovarian cancer through its interaction with LAMP1 and the PI3K/Akt/mTOR signaling pathway. These findings shed light on new therapeutic targets for ovarian cancer, a malignancy known for its poor prognosis and resistance to immune checkpoint inhibitors.

The latest research published in Genes & Diseases unveils groundbreaking insights into the role of the aging process and the associated factor EMP1 in the progression of resectable pancreatic cancer (PC). The study, conducted by a team of researchers from the University of Chinese Academy of Sciences and Chongqing Medical University, has established a prognostic model that links EMP1 expression with adverse clinical outcomes, particularly among older PC patients.